---
company: Aurinia Pharmaceuticals Inc.
ticker: AUPH
form: 8-K
filed: 2026-10-30
accepted: 2026-10-30T12:03:31+00:00
accession: 0001600620-26-000074
source: https://www.sec.gov/Archives/edgar/data/1600620/000160062026000074/
quarterly_report: https://www.sec.gov/Archives/edgar/data/1600620/000160062026000075/
---

# Aurinia Pharmaceuticals (AUPH) Q3 2026 earnings

## Header

- Company: Aurinia Pharmaceuticals Inc.
- Reported: 2026-10-30 08:03 BMO ET
- Source: 8-K only — accession 0001600620-26-000074, Item 2.02 + Exhibit 99.1
- Verdict: Revenue and net income grew for the nine months, but Q3 net income and EPS declined sequentially despite higher revenue.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---:|---:|---|---|
| Revenue | $83.7M | +14% | — | Ex. 99.1 |

## Revenue breakdown

| Segment | Actual | YoY | Share of revenue | Note |
|---|---:|---:|---:|---|
| Net product sales | $79.4M | +12% | 95% | LUPKYNIS |
| License, collaboration and royalty revenue | $4.3M | +54% | 5% | — |

## Margins and costs

- Gross margin: 90.1% (prior 88.8%, change +1.3 pp)
- Operating expenses: $48.3M (+10.7% YoY)
- One-offs in the quarter: Restructuring $0 (vs $1.6M in prior year); Other (income) expense, net $1,267 (vs $929)
- Effective tax rate: 18.1% (prior-year 1.3%, year-to-date 21.2%)
- Non-GAAP bridge: Deferred income tax, share-based compensation, amortization and depreciation, foreign exchange, net amortization of premiums and discounts, other

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---:|
| Cash, cash equivalents and restricted cash | $46.1M | $179.8M | $44.2M | -74.4% |
| Short-term investments | $440.7M | $263.3M | $45.5M | +67.5% |
| Total assets | $825.7M | $792.3M | $751.6M | +4.2% |
| Total revenue (9M) | $244.6M | $160.9M | $205.9M | +18.8% |
| Net income (9M) | $103.5M | $71.8M | $76.4M | +35.5% |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---:|---:|---:|
| Total revenue 2026 | $325M to $330M | $315M to $325M | +1.0 pp to +1.5 pp |
| Net product sales 2026 | $310M to $315M | $305M to $315M | +0.5 pp |

## What drove it

- Revenue story: Total revenue grew 14% YoY to $83.7M, driven by a 12% increase in LUPKYNIS net product sales to $79.4M and a 54% jump in license, collaboration and royalty revenue to $4.3M.
- EPS story: Q3 EPS was flat YoY at $0.23, but declined sequentially from $0.28 in Q2, despite higher revenue, due to increased operating expenses and a lower tax rate.
- One-off check: Restructuring expense of $0 in Q3 2026, compared to $1.6M in Q3 2025.

## The good

- License, collaboration and royalty revenue grew 54% YoY
- Net product sales grew 12% YoY
- Cash and investments increased to $486.9M

## The bad

- Q3 net income declined 15.4% sequentially to $31.7M
- Q3 diluted EPS declined 13.2% sequentially to $0.23
- Cash flows from operating activities declined 44.3% sequentially to $46.4M

## The ugly

- Operating expenses increased 10.7% YoY to $48.3M, driven by higher R&D and SG&A

## Open questions

- What caused the sequential decline in net income and EPS despite revenue growth?
- What drove the significant sequential decrease in cash flows from operating activities?

## Full release

### Aurinia Pharmaceuticals (AUPH) earnings release, October 30, 2026

Aurinia Pharmaceuticals Inc. (AUPH) · Form 8-K, Item 2.02 · Filed 2026-10-30 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1600620/000160062026000074/)

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended

September 30, 2026 and Provides Update on Recent Business Progress

EDMONTON, Alberta – October 30, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2026 and provided an update on recent business progress.

Financial Results

• Total Revenue:

For the three and nine months ended September 30, 2026, total revenue was $83.7 million and $244.6 million, up 14% and 19%, respectively, from $73.5 million and $205.9 million, respectively, in the same periods of 2025. – Net Product Sales:

For the three and nine months ended September 30, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $79.4 million and $232.4 million, up 12% and 18%, respectively, from $70.6 million and $197.2 million, respectively, in the same periods of 2025. – License, Collaboration and Royalty Revenue:

For the three and nine months ended September 30, 2026, license, collaboration and royalty revenue was $4.3 million and $12.2 million, up 54% and 39%, respectively, from $2.8 million and $8.8 million, respectively, in the same periods of 2025.

• Net Income:

For the three and nine months ended September 30, 2026, net income before taxes was $38.7 million and $131.4 million, up 21% and 67%, respectively, from $32.0 million and $78.5 million, respectively, in the same periods of 2025. For the three and nine months ended September 30, 2026, net income was $31.7 million and $103.5 million, flat and up 35%, respectively, from $31.6 million and $76.4 million, respectively, in the same periods of 2025.

• Diluted Earnings per Share:

For the three and nine months ended September 30, 2026, diluted earnings per share was $0.23 and $0.76, flat and up 38%, respectively, from $0.23 and $0.55, respectively, in the same periods of 2025.

• Cash Flows from Operating Activities:

For the three and nine months ended September 30, 2026, cash flows from operating activities were $46.4 million and $131.5 million, up 4% and 46%, respectively, from $44.5 million and $90.0 million, respectively, in the same periods of 2025.

Cash Position

As of September 30, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $486.9 million, compared to $398.0 million at December 31, 2025. For the nine months ended September 30, 2026, cash outflows from financing activities were $53.2 million, which primarily included the repurchase of 5.0 million of the Company’s common shares for $74.9 million, partially offset by proceeds from issuance of common shares for equity awards, net of tax withholding payments, of $35.9 million.

2026 Total Revenue and Net Product Sales Guidance

Aurinia is increasing its total revenue guidance for 2026 from a range of $315 million to $325 million to a range of $325 million to $330 million. Aurinia is narrowing its net product sales guidance for 2026 from a range of $305 million to $315 million to a range of $310 million to $315 million.¹

Recent Development Progress

LUPKYNIS

Aurinia has recently initiated PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis. Belimumab is a B cell-activating factor (BAFF) inhibitor indicated for the treatment of both systemic lupus erythematosus (SLE) and lupus nephritis. Obinutuzumab is a CD20-directed cytolytic antibody indicated for the treatment of lupus nephritis. Anifrolumab is a type 1 interferon receptor antagonist indicated for the treatment of SLE. PRESERVE will investigate whether the multi-target approach of combining LUPKYNIS with these biologic agents improves outcomes in patients with lupus nephritis. Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study’s primary endpoint is the proportion of patients achieving complete renal response (CRR) at 6 months.

Aritinercept

Aritinercept is a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Aurinia has now initiated clinical development of aritinercept in four potential indications.

About Aurinia

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS®

(voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

Forward-Looking Statements... (truncated) Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com.

Investor Inquiries ir@auriniapharma.com²

#### Financial statements

##### Income Statement (Three Months Ended — (in thousands, except per share data))

| | Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 |
|---|---:|---:|---:|---:|
| **Revenue** | | | | |
| Net product sales | 79,418 | 70,627 | 232,393 | 197,172 |
| License, collaboration and royalty revenue | 4,281 | 2,841 | 12,231 | 8,769 |
| Total revenue | 83,699 | 73,468 | 244,624 | 205,941 |
| **Operating expenses** | | | | |
| Cost of revenue | 8,306 | 8,177 | 21,366 | 23,866 |
| Selling, general and administrative | 24,684 | 26,182 | 70,221 | 72,539 |
| Research and development | 16,613 | 8,435 | 37,133 | 21,610 |
| Restructuring |  |  |  | 1,647 |
| Other (income) expense, net | -1,267 | 929 | -7,222 | 14,604 |
| Total operating expenses | 48,336 | 43,723 | 121,498 | 134,266 |
| Income from operations | 35,363 | 29,745 | 123,126 | 71,675 |
| Interest income | 4,219 | 3,316 | 11,127 | 10,075 |
| Interest expense | -867 | -1,099 | -2,827 | -3,283 |
| Net income before income taxes | 38,715 | 31,962 | 131,426 | 78,467 |
| Income tax expense | 7,012 | 411 | 27,954 | 2,059 |
| Net income | 31,703 | 31,551 | 103,472 | 76,408 |
| **Earnings per share** | | | | |
| Basic | 0.24 | 0.24 | 0.78 | 0.57 |
| Diluted | 0.23 | 0.23 | 0.76 | 0.55 |
| **Shares used in computing earnings per share** | | | | |
| Basic | 133,434 | 131,808 | 131,967 | 135,163 |
| Diluted | 135,173 | 136,008 | 135,346 | 138,959 |

##### Balance Sheet ((in thousands))

| | September 30, 2026 – (Unaudited) | December 31, 2025 |
|---|---:|---:|
| **Current assets:** | | |
| Cash, cash equivalents and restricted cash | 46,145 | 80,213 |
| Short-term investments | 440,735 | 317,784 |
| Accounts receivable, net | 47,414 | 41,454 |
| Inventory | 43,728 | 45,690 |
| Prepaid expenses and deposits | 5,915 | 5,746 |
| Other current assets | 3,949 | 1,080 |
| Total current assets | 587,886 | 491,967 |
| Deferred tax assets, net | 170,652 | 176,194 |
| Finance right-of-use lease assets | 60,795 | 73,865 |
| Intangible assets, net | 3,169 | 3,761 |
| Property and equipment, net | 1,737 | 2,111 |
| Operating right-of-use lease assets | 1,372 | 3,596 |
| Other noncurrent assets | 93 | 93 |
| Total assets | 825,704 | 751,587 |
| **Current liabilities:** | | |
| Accounts payable | 3,014 | 3,313 |
| Accrued expenses | 63,299 | 66,621 |
| Finance lease liabilities, current portion | 16,150 | 16,523 |
| Deferred revenue | 10,413 | 3,720 |
| Operating lease liabilities, current portion | 1,808 | 1,067 |
| Other current liabilities | 1,321 | 2,480 |
| Total current liabilities | 96,005 | 93,724 |
| Finance lease liabilities, less current portion | 39,028 | 52,322 |
| Deferred tax benefits | 23,128 |  |
| Deferred revenue, less current portion | 7,157 | 12,648 |
| Operating lease liabilities, less current portion | 1,677 | 4,900 |
| Other noncurrent liabilities | 1,190 | 6,662 |
| Total liabilities | 168,185 | 170,256 |
| **Shareholders' equity** | | |
| Common shares — no par value, unlimited shares authorized, 133,995 and 132,323 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | 1,127,503 | 1,120,035 |
| Additional paid-in capital | 77,044 | 111,263 |
| Accumulated other comprehensive loss | -1,132 | -599 |
| Accumulated deficit | -545,896 | -649,368 |
| Total shareholders' equity | 657,519 | 581,331 |
| Total liabilities and shareholders' equity | 825,704 | 751,587 |

##### Cash Flow (Nine Months Ended September 30, — (in thousands))

| | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| **Cash flows from operating activities:** | | |
| Net income | 103,472 | 76,408 |
| **Adjustments to reconcile net income to cash flows from operating activities:** | | |
| Deferred income tax | 28,670 |  |
| Share-based compensation | 8,097 | 7,950 |
| Amortization and depreciation | 14,491 | 14,585 |
| Foreign exchange (gain) loss on revaluation of Monoplant finance lease liability | -2,605 | 9,318 |
| Net amortization of premiums and discounts on investments | -6,141 | -7,844 |
| Other, net | -1,498 | 4,852 |
| **Net changes in operating assets and liabilities:** | | |
| Accounts receivable, net | -5,960 | 5,816 |
| Inventory | 1,962 | -5,565 |
| Prepaid expenses and other current assets | -2,983 | 940 |
| Other noncurrent operating assets |  | 730 |
| Accounts payable | -2,172 | -2,973 |
| Accrued expenses and other liabilities | -4,372 | -17,777 |
| Deferred revenue | 1,202 | 4,150 |
| Operating lease liabilities | -670 | -600 |
